Weekly paclitaxel as second/third-line treatment in advanced non-small cell lung cancer patients: efficacy and tolerability.

@article{Camps2005WeeklyPA,
  title={Weekly paclitaxel as second/third-line treatment in advanced non-small cell lung cancer patients: efficacy and tolerability.},
  author={Carlos Camps and Cristina Caballero and Ana Blasco and Mar{\'i}a Jos{\'e} Safont and A Berrocal and J Barrio Garde and Asunci{\'o}n Ju{\'a}rez and Rafael Sirera and Roy Martin Bremnes},
  journal={Anticancer research},
  year={2005},
  volume={25 6C},
  pages={4611-4}
}
BACKGROUND The aim of the present study was to evaluate the efficacy and toxicity of weekly paclitaxel as second- or third-line treatment in non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS The outcome measured in 37 patients were: response rates, symptom relief (dyspnoea, asthenia and pain), toxicity, overall survival (OS) and time to progression (TTP). RESULTS Objective response was seen in 8%, stable disease in 27% and disease progression in 62%. Three paclitaxel… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-6 of 6 extracted citations

Similar Papers

Loading similar papers…